Imaging Techniques for Multiple Sclerosis

Recruiting in Palo Alto (17 mi)

Overseen byBurcu Zeydan, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This purpose of this study is research the usefulness of MRI with PET/CT imaging for measuring brain inflammation and its relation to Multiple Sclerosis (MS).

Eligibility Criteria

This trial is for individuals with Multiple Sclerosis (MS) who are already part of certain MS studies or clinics, and healthy controls without inflammatory brain diseases. Participants must be able to lie still for imaging procedures and give consent. Pregnant or breastfeeding women, recent steroid users, and those with MRI safety risks like pacemakers can't join.

Inclusion Criteria

I do not have any inflammatory brain or spinal cord diseases.

Meet the requirements for one of the case or control groups

MS patients undergoing neurologic evaluation procedures as part of Understanding Sex Differences in Multiple Sclerosis Spectrum of Demyelinating Disorders (IRB# 19-002807) Study or the Mayo Clinic Neurology Multiple Sclerosis Clinic

+1 more

Exclusion Criteria

Women who are pregnant or cannot stop breastfeeding for 24 hours

I haven't taken any steroids in the last 2 weeks.

Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.

+1 more

Participant Groups

The study is testing the effectiveness of combining MRI scans with PET/CT imaging using C-11 ER176 Radiotracer and C11 Pittsburgh Compound B to measure brain inflammation in people with MS.

2Treatment groups

Experimental Treatment

Group I: Multiple Sclerosis GroupExperimental Treatment4 Interventions

Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB \& C-11 ER176

Group II: Healthy Control GroupExperimental Treatment4 Interventions

Subjects without inflammatory-demyelinating diseases of the central nervous system